Gilteritinib Exposure
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Conditions
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Trial Timeline
Jun 17, 2022 → May 4, 2025
NCT ID
NCT04691648About Gilteritinib Exposure
Gilteritinib Exposure is a pre-clinical stage product being developed by Astellas Pharma for Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation. The current trial status is completed. This product is registered under clinical trial identifier NCT04691648. Target conditions include Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04691648 | Pre-clinical | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation